Last update :
14/12/2024
Infostab
List of drugs
Summary lists
Search for compatibilities
Y-site compatibility table
References
Research teams
valistab
Poster
Links
Sponsors
Authors
User’s guide
Newsletter
References 3459
Type :
Journal
Web link :
http://link.springer.com/article/10.1007/s00280-013-2201-2
Research teams :
Whitehouse - Merck manufacturing Division
Authors :
Sun S, Schaller J, Placek J, Duersch B.
Title :
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Reference :
Cancer Chemother Pharmacol ; 72: 509-513. 2013
Level of Evidence :
Physical stability :
Chemical stability :
Other methods :
Comments :
Repeatability / reproducibility / standard range: results not provided or results outside specified values
The method is not specified (poster, letter to the editor)
Degradation products quantified but not identified
List of drugs
Dexamethasone sodium phosphate
0,1 mg/ml
+
Fosaprepitant dimeglumine
1 mg/ml
+
Fosaprepitant dimeglumine
1 mg/ml
25°C
24
1 mg/ml
+
Dexamethasone sodium phosphate
0,1 mg/ml
+
1 mg/ml
+
Granisetron hydrochloride
0,026 mg/ml
+
1 mg/ml
+
Methylprednisolone sodium succinate
0,7 mg/ml
+
1 mg/ml
+
Ondansetron hydrochloride
0,07 mg/ml
+
1 mg/ml
+
Palonosetron hydrochloride
2 µg/ml
1 mg/ml
+
Tropisetron hydrochloride
0,043 mg/ml
+
Granisetron hydrochloride
0,026 mg/ml
+
Fosaprepitant dimeglumine
1 mg/ml
+
Methylprednisolone sodium succinate
0,7 mg/ml
+
Fosaprepitant dimeglumine
1 mg/ml
+
Ondansetron hydrochloride
0,07 mg/ml
+
Fosaprepitant dimeglumine
1 mg/ml
+
Palonosetron hydrochloride
2 µg/ml
+
Fosaprepitant dimeglumine
1 mg/ml
Tropisetron hydrochloride
0,043 mg/ml
+
Fosaprepitant dimeglumine
1 mg/ml
+
Mentions Légales
